The risks and benefits of early immunosuppression and biological therapy

Digestive Diseases

Volumn 30, Issue SUPPL. 3, 2012, Pages 100-106

  Sands, Bruce E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biological therapy; Crohn's disease; Immune suppression; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

ARTICLE; BIOLOGICAL THERAPY; COMBINATION CHEMOTHERAPY; CROHN DISEASE; EARLY INTERVENTION; ENDOSCOPY; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84872064143     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000342731     Document Type: Article

References (36)

1. Stallmach A, Schuppan D, Riese HH, Matthes H, Riecken EO: Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992;102:1920-1929.
2. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP: Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-250. (Pubitemid 34784976)
3. Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105:1716-1723. (Pubitemid 24002788)
4. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF: Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-1363.
5. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-459. (Pubitemid 38182302)
6. Negron ME, Frolkis AD, Dykeman J, Barkema H, Rioux KP, De Buck J, Checkley S, Panaccione R, Ghosh S: Risk of surgery following diagnosis in adult and pediatric ulcerative colitis patients: a systematic review and meta-analysis: Dig Dis Week, San Diego, 2012.
7. Wolters FL, Russel MG, Stockbrugger RW: Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004;20:483-496. (Pubitemid 39243894)
8. Munkholm P, Langholz E, Davidsen M, Binder V: Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
9. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology 2001;121:255-260. (Pubitemid 32729372)
10. Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL: Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-1435; quiz 1436. (Pubitemid 351813915)
11. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R: Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-235. (Pubitemid 24092870)
12. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP: Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-241. (Pubitemid 40139240)
13. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Veres G, Lovasz BD, Szathmari M, Kiss LS, Lakatos L: Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from western Hungary between 1977-2009. Am J Gastroenterol 2012;107:579-588.
14. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panes J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lemann M: Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis 2011;17:1415-1422.
15. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE: Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-450 e441; quiz 716.
16. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005;128:862-869. (Pubitemid 40523539)
17. Nepal S, Bahuva R, Shen B, Atreja A: Early initiation of biologics and immunomodulators decrease the need for surgery in enterographyproven stricturing Crohn's disease. Dig Dis Week, San Diego, 2012.
18. Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, Sandborn WJ: Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-1582.
19. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ: Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 2010;59:141-147.
20. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
21. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D: Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-667. (Pubitemid 351284485)
22. Sans M, Roman ALS, Esteve M, Bermejo F, Garcia-Sanchez V, Torres Y, Domenech E, Piqueras M, Aceituno M, Gomez-Garcia M, Taxonera C, Gishen JP, Gutierrez A, Gomollon F, Ginard D, Bernal A, Gimeno-Garcia AZ, Munoz C, Mearin F, Minguez M, Barreirode Acosta M, Calvet X, Buenestado J, Merino O, Barrachina M, Bujanda L, Marios M, Calvo MM, Garcia E, Montoro MA, Justiniano JMI, Andrea M, Hernandez V, Hinojosa J, Panes J: Early use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients. Gastroenterology 2011;140:S109-S109.
23. Cosnes J, Bourrier A, Laharie D, Bouhnik Y, Nahon S, Bonnet J, Carbonnel F, Dupas JL, Marie RJ, Jouet P, Savoye G, Mary JY, Colombel JF: Accelerated step-care therapy with early azathioprine (aza) vs. conventional step-care therapy in Crohn's disease: a randomized study. Dig Dis Week, San Diego, 2012.
24. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-1395.
25. Lichtenstein GR, Cohen RD, Feagan BG, Salzberg BA, Turner M, Mink D, Langholff WK, Diamond R, Sandborn WJ: Safety of infliximab and other Crohn's disease therapies: TREAT TM registry data with a mean of 5 years of follow-up. Gastroenterology 2011;140:S773-S773.
26. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-630.
27. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE: Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-881.
28. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, Hebuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadie M, Hermine O, Faivre J, Carrat F: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617-1625.
29. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R: Long-term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002;97:947-953. (Pubitemid 34408253)
30. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J: Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004;99:2376-2384. (Pubitemid 40039369)
31. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J: Predictors of Crohn's disease. Gastroenterology 2006;130:650-656. (Pubitemid 43374514)
32. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Hemker MO, Leleiko N, Crandall W, Langton C, Landers C, Taylor KD, Targan SR, Rotter JI, Markowitz J, Hyams J: Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105-1111.
33. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H: Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360-367. (Pubitemid 43381681)
34. Kugathasan S, Collins N, Maresso K, Hoffmann RG, Stephens M, Werlin SL, Rudolph C, Broeckel U: CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease. Clin Gastroenterol Hepatol 2004;2:1003-1009. (Pubitemid 39539750)
35. Lapidus A, Bernell O, Hellers G, Lofberg R: Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients. Gastroenterology 1998;114:1151-1160. (Pubitemid 28243900)
36. Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK: Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003;98:2712-2718. (Pubitemid 38020113)